Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.
Lifordi Immunotherapeutics has raised $42.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2025.
Lifordi Immunotherapeutics's investors include ARCH Venture Partners, Sanofi Ventures, Atlas Venture, 5AM Ventures.
Lifordi Immunotherapeutics is headquartered in Burlington, United States.
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.
Lifordi Immunotherapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lifordi Immunotherapeutics — Funding & Investors." VCBacked, November 19, 2025, https://www.vcbacked.co/company/lifordi-immunotherapeutics. Accessed July 21, 2026.
VCBacked. (2025). Lifordi Immunotherapeutics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/lifordi-immunotherapeutics
{{cite web |title=Lifordi Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lifordi-immunotherapeutics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated